Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase III safety analysis in nucleoside-naive and lamivudine-refractory patients

被引：0
|
作者：
Sollano, J
Schiff, E
Carrilho, F
Raptopoulou-Gigi, M
Cooney, E
Hindes, R
Cross, A
DeHertogh, D
机构：
[1] Univ Santo Tomas, Manila, Philippines
[2] Univ Miami, Miami, FL 33152 USA
[3] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil
[4] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece
[5] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源：
ANTIVIRAL THERAPY | 2004年 / 9卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：H24 / H24
页数：1
相关论文
共 50 条
  • [1] Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase III safety analysis in nucleoside-naive and lamivudine-refractory patients
    Sollano, J
    Schiff, E
    Carrilho, F
    Raptopoulou-Gigi, M
    Cooney, E
    Hindes, R
    Cross, A
    Dehertogh, D
    HEPATOLOGY, 2004, 40 (04) : 665A - 665A
  • [2] Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results
    Gigi, M. Raptopoulou
    Manns, M.
    Cooney, E.
    Hindes, R.
    Cross, A.
    Wilber, R.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S95 - S95
  • [3] Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: Phase 2/3 safety results
    Gish, RG
    Sherman, M
    Lok, AS
    Pockros, PJ
    Raptopoulou-Gigi, M
    Sollano, JD
    Chang, TT
    Cooney, E
    Hindes, RG
    Yang, JY
    Cross, AP
    Wilber, RB
    GASTROENTEROLOGY, 2005, 128 (04) : A693 - A693
  • [4] Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: Phase II/II safety results
    Manns, MP
    Raptopoulou-Gigi, M
    Sollano, J
    Gish, RG
    Chang, TT
    Sherman, M
    Yurdaydin, C
    Shouval, D
    Lok, AS
    Cooney, E
    Hindes, R
    Yang, J
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 185 - 185
  • [5] Entecavir (ETV) is well tolerated for the treatment of nucleoside-naive and Lamivudine-refractory chronic hepatitis B: phase 2/3 safety results
    Gigi, M. R.
    Manns, M.
    Cooney, E.
    Hindes, R.
    Cross, A.
    Wilber, R.
    LIVER INTERNATIONAL, 2006, 26 : 56 - 56
  • [6] The cost-effectiveness of entecavir in the longterm treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B patients in Sweden
    Cerri, K. H.
    Yuan, Y.
    Zammit, D. C.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A301
  • [7] Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
    Guangbi Yao
    Xiaqiu Zhou
    Daozheng Xu
    Baoen Wang
    Hong Ren
    Jessica Liu
    Dong Xu
    Laurie MacDonald
    Hepatology International, 2007, 1 : 373 - 381
  • [8] Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
    Yao, Guangbi
    Zhou, Xiaqiu
    Xu, Daozheng
    Wang, Baoen
    Ren, Hong
    Liu, Jessica
    Xu, Dong
    MacDonald, Laurie
    HEPATOLOGY INTERNATIONAL, 2007, 1 (03) : 373 - 381
  • [9] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    Dehertogh, D
    Apelian, D
    HEPATOLOGY, 2004, 40 (04) : 193A - 193A
  • [10] Is Entecavir Ideal for the Treatment of Lamivudine-Refractory Chronic Hepatitis B?
    Su, Chien-Wei
    Wu, Jaw-Ching
    Lee, Shou-Dong
    HEPATOLOGY, 2008, 48 (05) : 1726 - 1727
12345